Zofenoprilat
Based on 1 publication(s) in Google Scholar
Zofenoprilat is an angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 1.7 nM. Zofenoprilat exerts cardioprotective and renoprotective effects by inhibiting angiotensin II expression and lowering blood pressure. Zofenoprilat promotes NO production and reduces endothelin-1 (ET-1) expression. Zofenoprilat decreases TNFα-induced ROS production and protects vascular endothelial function. Zofenoprilat regulates oxidative stress-related molecules and possesses antioxidant activity. Zofenoprilat can be used in studies related to hypertension and congestive heart failure.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 75176-37-3
- Formule: C15H19NO3S2
- Masse moléculaire:325.45
-
Stockage:Pure form -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Zofenoprilat
More
Activité biologique
Zofenoprilat (10-8 M; 8 h) reduces the spontaneous ET-1 secretion level of HUVECs by 42%[2].
Zofenoprilat (10-8 M; 8 h) increases NOx production in HUVECs by 110%[2].
Zofenoprilat (10-8 M) more effectively reduces the production of reactive oxygen species (ROS) in TNFα-stimulated HUVECs than Captopril[2].
Zofenoprilat (10-8 M) significantly inhibits TNFα-induced GSH depletion in HUVECs[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 75176-37-3
-
Appearance Oil
-
Masse moléculaire 325.45
-
Formule C15H19NO3S2
-
Color Colorless to light yellow
-
SMILES
SC[C@@H](C)C(N1[C@@H](C[C@@H](C1)SC2=CC=CC=C2)C(O)=O)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Pure form -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
Pureté et documentation
-
Fiche technique (277 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Ranadive SA, et al. Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharm Res. 1992;9(11):1480-1486. [Content Brief]
[2]. Desideri G, et al. Different effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: evidence of an oxidant-sensitive pathway. Mediators Inflamm. 2008;2008:305087. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Zofenoprilat Related Classifications
HY-133829 Related Classifications
Powered by Bioz